The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia
- PMID: 34080325
- PMCID: PMC8290240
- DOI: 10.1002/cam4.4024
The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia
Abstract
Background: Treatment on risk adapted intensive pediatric protocols has improved outcome for teenagers and young adults (TYA) with T-cell acute lymphoblastic leukemia (T-ALL). Understanding the biology of disease in this age group and the genetic basis of relapse is a key goal as patients with relapsed/refractory disease have poor outcomes with conventional chemotherapy and novel molecular targets are required. This study examines the question of whether TYA T-ALL has a specific biological-molecular profile distinct from pediatric or adult T-ALL.
Methods: Genomic characterization was undertaken of a retrospective discovery cohort of 80 patients aged 15-26 years with primary or relapsed T-ALL, using a combination of Genome-Wide Human SNP Array 6.0, targeted gene mutation and promoter methylation analyses. Findings were confirmed by MLPA, real-time quantitative PCR, and FISH. Whole Exome Sequencing was performed in 4 patients with matched presentation and relapse to model clonal evolution. A prevalence analysis was performed on a final data set of 1,792 individual cases to identify genetic lesions with age specific frequency patterns, including 972 pediatric (1-14 years), 439 TYA (15-24 years) and 381 adult (≥25 years) cases. These cases were extracted from 19 publications with comparable genomic data identified through a PubMed search.
Results: Genomic characterization of this large cohort of TYA T-ALL patients identified recurrent isochromosome 7q i(7q) in our discovery cohort (n = 3). Prevalence analysis did not identify any age specific genetic abnormalities. Genomic analysis of 6 pairs of matched presentation - relapsed T-ALL established that all relapses were clonally related to the initial leukemia. Whole exome sequencing analysis revealed recurrent, targetable, mutations disrupting NOTCH, PI3K/AKT/mTOR, FLT3, NRAS as well as drug metabolism pathways.
Conclusions: All genetic aberrations in TYA T-ALL occurred with an incidence similar or intermediate to that reported in the pediatric and adult literature, demonstrating that overall TYA T-ALL exhibits a transitional genomic profile. Analysis of matched presentation - relapse supported the hypothesis that relapse is driven by the Darwinian evolution of sub-clones associated with drug resistance (NT5C2 and TP53 mutations) and re-iterative mutation of known key T-ALL drivers, including NOTCH1.
Keywords: T-ALL; clonal selection; genomics; relapse; teenagers and young adults.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
NOTCH1 pathway activating mutations and clonal evolution in pediatric T-cell acute lymphoblastic leukemia.Cancer Sci. 2019 Feb;110(2):784-794. doi: 10.1111/cas.13859. Epub 2019 Jan 9. Cancer Sci. 2019. PMID: 30387229 Free PMC article.
-
RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.Haematologica. 2016 Aug;101(8):941-50. doi: 10.3324/haematol.2015.139410. Epub 2016 May 5. Haematologica. 2016. PMID: 27151993 Free PMC article.
-
Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation.Haematologica. 2015 Nov;100(11):1442-50. doi: 10.3324/haematol.2015.129692. Epub 2015 Aug 20. Haematologica. 2015. PMID: 26294725 Free PMC article. Clinical Trial.
-
The genomic landscape of acute lymphoblastic leukemia in children and young adults.Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):174-80. doi: 10.1182/asheducation-2014.1.174. Epub 2014 Nov 18. Hematology Am Soc Hematol Educ Program. 2014. PMID: 25696852 Review.
-
[Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].Beijing Da Xue Xue Bao Yi Xue Ban. 2013 Apr 18;45(2):327-32. Beijing Da Xue Xue Bao Yi Xue Ban. 2013. PMID: 23591360 Review. Chinese.
Cited by
-
Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol.Blood Neoplasia. 2024 Sep 16;2(1):100041. doi: 10.1016/j.bneo.2024.100041. eCollection 2025 Feb. Blood Neoplasia. 2024. PMID: 40546727 Free PMC article.
-
Unraveling the Genetic Heterogeneity of Acute Lymphoblastic Leukemia Based on NGS Applications.Cancers (Basel). 2024 Nov 26;16(23):3965. doi: 10.3390/cancers16233965. Cancers (Basel). 2024. PMID: 39682152 Free PMC article. Review.
-
Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia.Cancer Biol Ther. 2025 Dec;26(1):2457777. doi: 10.1080/15384047.2025.2457777. Epub 2025 Jan 25. Cancer Biol Ther. 2025. PMID: 39862423 Free PMC article.
-
TNFAIP3 mutation is an independent poor overall survival factor for patients with T-cell acute lymphoblastic leukemia.Cancer Med. 2023 Feb;12(4):3952-3961. doi: 10.1002/cam4.5196. Epub 2022 Sep 3. Cancer Med. 2023. PMID: 36056685 Free PMC article.
-
Novel MYCBP::EHD2 and RUNX1::ZNF780A Fusion Genes in T-cell Acute Lymphoblastic Leukemia.Cancer Genomics Proteomics. 2023 Jan-Feb;20(1):51-63. doi: 10.21873/cgp.20364. Cancer Genomics Proteomics. 2023. PMID: 36581344 Free PMC article.
References
-
- Beldjord K, Chevret S, Asnafi V, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123(24):3739‐3749. - PubMed
-
- Patrick K, Wade R, Goulden N, et al. Outcome for children and young people with early T‐cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2014;166(3):421‐424. - PubMed
-
- Patrick K, Wade R, Goulden N, et al. Improved outcome for children and young people with T‐acute lymphoblastic leukaemia: results of the UKALL 2003 trial. Blood. 2014;124(21):3702.
-
- Sellar RS, Rowntree C, Vora AJ, et al. Relapse in teenage and young adult patients treated on a paediatric minimal residual disease stratified ALL treatment protocol is associated with a poor outcome: results from UKALL2003. Br J Haematol. 2018;181(4):515‐522. - PubMed
Publication types
MeSH terms
Grants and funding
- KKLF417/Kay Kendall Leukaemia Fund
- Fundação do Cancer, SwissBridge Fund
- 134253/The Hungarian National Research, Development and Innovation Office-NKFIH
- E-26/202.577/2019/FAPERJ
- BO/00320/18/5/Hungarian Academy of Sciences
- 310877/2019-5/INCA, CNPq
- ÚNKP-20-5-SE-22/New National Excellence Program of the Ministry for Innovation and Technology
- The Institute of Cancer Research
- Lady Tata Memorial Trust-LTMT International Award for Research in Leukaemia and the Ministry of Health, INCA-Brazil
- 2011/01/The European Hematology Association-EHA Partner Fellowship
- 119950/The Hungarian National Research, Development and Innovation Office-NKFIH
- Leukaemia & Lymphoma Research
- 739593/EU's Horizon 2020 Research and Innovation Program
- 105104/Z/14/Z/WT_/Wellcome Trust/United Kingdom
- Bloodwise
- E-26/110.712/2012/FAPERJ
- 301594/2015-5/INCA, CNPq
- WT_/Wellcome Trust/United Kingdom
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous